These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196 [TBL] [Abstract][Full Text] [Related]
6. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701 [TBL] [Abstract][Full Text] [Related]
7. 11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: a putative role in castration resistant prostate cancer? Storbeck KH; Bloem LM; Africander D; Schloms L; Swart P; Swart AC Mol Cell Endocrinol; 2013 Sep; 377(1-2):135-46. PubMed ID: 23856005 [TBL] [Abstract][Full Text] [Related]
8. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287 [TBL] [Abstract][Full Text] [Related]
9. 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer. Uemura M; Honma S; Chung S; Takata R; Furihata M; Nishimura K; Nonomura N; Nasu Y; Miki T; Shuin T; Fujioka T; Okuyama A; Nakamura Y; Nakagawa H Cancer Sci; 2010 Aug; 101(8):1897-904. PubMed ID: 20560974 [TBL] [Abstract][Full Text] [Related]
10. The role of adrenal derived androgens in castration resistant prostate cancer. Barnard M; Mostaghel EA; Auchus RJ; Storbeck KH J Steroid Biochem Mol Biol; 2020 Mar; 197():105506. PubMed ID: 31672619 [TBL] [Abstract][Full Text] [Related]
11. Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. Hoang DT; Iczkowski KA; Kilari D; See W; Nevalainen MT Oncotarget; 2017 Jan; 8(2):3724-3745. PubMed ID: 27741508 [TBL] [Abstract][Full Text] [Related]
12. Reconsideration of progression to CRPC during androgen deprivation therapy. Mizokami A; Namiki M J Steroid Biochem Mol Biol; 2015 Jan; 145():164-71. PubMed ID: 24717975 [TBL] [Abstract][Full Text] [Related]
13. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis. Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548 [TBL] [Abstract][Full Text] [Related]
14. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Sharifi N Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793 [TBL] [Abstract][Full Text] [Related]
15. Targeting extra-gonadal androgens in castration-resistant prostate cancer. Grist E; de Bono JS; Attard G J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387 [TBL] [Abstract][Full Text] [Related]
16. Steroidogenesis in castration-resistant prostate cancer. Shiota M; Endo S; Blas L; Fujimoto N; Eto M Urol Oncol; 2023 May; 41(5):240-251. PubMed ID: 36376200 [TBL] [Abstract][Full Text] [Related]
17. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758 [TBL] [Abstract][Full Text] [Related]
18. 11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. Pretorius E; Africander DJ; Vlok M; Perkins MS; Quanson J; Storbeck KH PLoS One; 2016; 11(7):e0159867. PubMed ID: 27442248 [TBL] [Abstract][Full Text] [Related]
19. Intracrine androgen biosynthesis in renal cell carcinoma. Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524 [TBL] [Abstract][Full Text] [Related]
20. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer. Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]